2 results
Approved WMOCompleted
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
Approved WMORecruiting
Primary objectiveTo confirm superiority of oral semaglutide at the maximum tolerated dose* (3 mg, 7 mg or 14 mg) versus placebo on glycaemic control in children and adolescents (age 10 to <18 years) with type 2 diabetes on a background…